Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T Retreatment in mCRPC
NCT01338012Phase 2Terminated
- Sponsor
- Dendreon
- Start
- Dec 2011
- Primary completion
- Apr 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dendreon. Started Dec 2011; status: terminated.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01338012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01338012.